RecruitingPhase 2NCT05009927

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

Randomized, Multicentre, Phase II Study Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After at Least 10 Years of Treatment in Patients With Locally Advanced/Metastatic Gastrointestinal Stromal Tumors (GISTs)


Sponsor

Centre Leon Berard

Enrollment

50 participants

Start Date

Jan 3, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This is a 2 arms study concerning patients under imatinib treatment for at least 10 years of treatment with locally advanced/metastatic GIST. In the first arm, patients will discontinue Imatinib treatment. This arm will allow to determine if the re-introduction of Imatinib at relapse is still an efficient treatment for the control of disease. In the second arm, patients will continue Imatinib treatment, allowing to determine if the continuation of this treatment is efficient for disease control, by the rate of non-progression disease.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Imatinib tablets for people with advanced gastrointestinal stromal tumor (gist), c-kit mutation, and other related conditions. The study is currently recruiting participants at 13 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGImatinib tablets

Imatinib interruption


Locations(13)

CHU Besançon

Besançon, France

Institut Bergonié

Bordeaux, France

CHU Dupuytren

Limoges, France

Centre Léon Bérard

Lyon, France

Institut Paoli Calmettes

Marseille, France

Institut Curie

Paris, France

CHU de Reims

Reims, France

Centre Eugène Marquis

Rennes, France

Institut de Cancérologie de l'Ouest - Site Réné Gauducheau

Saint-Herblain, France

Institut de Cancérologie Lucien NEUWIRTH

Saint-Paul-en-Jarez, France

Institut Claudius Regaud

Toulouse, France

Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, France

Institut Goustave Roussy

Villejuif, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05009927


Related Trials